American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
BI
BIO-PATH HOLDINGS, INC.
$0.04
+11.11%
OTC: BPTH · 15-min delayed
$0Revenue · FY2018
-$9.9MNet income
BPTHOTC
About BIO-PATH HOLDINGS, INC.
BIO-PATH HOLDINGS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2018
- $0
- Net income
- -$9.9M
- Total assets
- $3.9M
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue Net income
FY 2024
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.0M
- Operating income
- -$12.0M
- Income tax
- $0
- Net income
- -$9.9M
- EPS (basic)
- $-4.12
- EPS (diluted)
- $-4.12
Balance sheet
- Total assets
- $3.9M
- Current assets
- $3.8M
- Total liabilities
- $3.7M
- Current liabilities
- $3.3M
- Shareholders’ equity
- $154.0K
Cash flow
- Operating cash flow
- -$10.6M
- Investing cash flow
- -$121.0K
- Financing cash flow
- $10.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- EPS (diluted)
- $-4.12
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $9.9M in FY2018.
- Trading 82% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIO-PATH HOLDINGS, INC..
Write a review
Newsroom
News about BIO-PATH HOLDINGS, INC.
Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings Provides 2025 Clinical and Operational Update
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
News & sentiment via Polygon.io
Explore
Browse all →
